A broader lens on tuberculosis cost-effectiveness analysis : How patient-incurred costs and post-tuberculosis outcomes reshape estimates in a multi-country study
Tuberculosis (TB) remains a major public health challenge, with financial and health impacts extending beyond treatment. Both the perspective adopted in cost-effectiveness analyses-which critically determines choices such as the inclusion of patient-incurred costs-and the extent to which long-term post-treatment considerations are incorporated have important policy implications. This study examine
